Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 192

1.

Radiation Modeling and Finite Cloud Effects for Atmospheric Dispersion Calculations in Near-field Applications: Modeling of the Full Scale RDD Experiments with Operational Models in Canada, Part II.

Lebel L, Bourgouin P, Chouhan S, Ek N, Korolevych V, Malo A, Bensimon D, Erhardt L.

Health Phys. 2016 May;110(5):518-25. doi: 10.1097/HP.0000000000000366.

PMID:
27023038
2.

The Sensitivity of Atmospheric Dispersion Calculations in Near-field Applications: Modeling of the Full Scale RDD Experiments with Operational Models in Canada, Part I.

Lebel L, Bourgouin P, Chouhan S, Ek N, Korolevych V, Malo A, Bensimon D, Erhardt L.

Health Phys. 2016 May;110(5):499-517. doi: 10.1097/HP.0000000000000365.

PMID:
27023037
3.

Deposition Measurements From the Full-Scale Radiological Dispersal Device Field Trials.

Erhardt L, Lebel L, Korpach E, Berg R, Inrig E, Watson I, Liu C, Gilhuly C, Quayle D.

Health Phys. 2016 May;110(5):442-57. doi: 10.1097/HP.0000000000000444.

PMID:
27023032
4.

Real Time in Situ Gamma Radiation Measurements of the Plume Evolution from the Full-Scale Radiological Dispersal Device Field Trials.

Korpach E, Berg R, Erhardt L, Lebel L, Liu C.

Health Phys. 2016 May;110(5):427-35. doi: 10.1097/HP.0000000000000497.

PMID:
27023030
5.

Overview of the Full-scale Radiological Dispersal Device Field Trials.

Green AR, Erhardt L, Lebel L, Duke MJ, Jones T, White D, Quayle D.

Health Phys. 2016 May;110(5):403-17. doi: 10.1097/HP.0000000000000503.

PMID:
27023028
6.

Introduction to the Special Issue on Experiments Involving the Outdoor Energetic Release of Radioactive Materials.

Erhardt L.

Health Phys. 2016 May;110(5):399-400. doi: 10.1097/HP.0000000000000480. No abstract available.

PMID:
27023026
7.

Cheyne-Stokes respiration is not related to quality of life or sleepiness in heart failure.

Midgren B, Mared L, Franklin KA, Berg S, Erhardt L, Cline C.

Clin Respir J. 2010 Jan;4(1):30-6. doi: 10.1111/j.1752-699X.2009.00139.x.

PMID:
20298415
8.

Gender differences in variables related to B-natriuretic peptide, left ventricular ejection fraction and mass, and peak oxygen consumption, in patients with heart failure.

Tasevska-Dinevska G, Kennedy LM, Cline-Iwarson A, Cline C, Erhardt L, Willenheimer R.

Int J Cardiol. 2011 Jun 16;149(3):364-71. doi: 10.1016/j.ijcard.2010.02.018. Epub 2010 Mar 3.

PMID:
20202706
9.

Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.

Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E; Atrial Arrhythmia Conversion Trial Investigators.

Circ Arrhythm Electrophysiol. 2009 Dec;2(6):652-9. doi: 10.1161/CIRCEP.109.870204.

10.

Radiological hazard estimates from contaminated C7 canisters on the C4 protective mask.

Waller EJ, Erhardt L.

Health Phys. 2009 Apr;96(4):450-5. doi: 10.1097/01.HP.0000338340.60296.5c.

PMID:
19276705
11.

Cigarette smoking: an undertreated risk factor for cardiovascular disease.

Erhardt L.

Atherosclerosis. 2009 Jul;205(1):23-32. doi: 10.1016/j.atherosclerosis.2009.01.007. Epub 2009 Jan 15. Review.

PMID:
19217623
12.

The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.

Brugts JJ, de Maat MP, Boersma E, Witteman JC, van Duijn C, Uitterlinden AG, Bertrand M, Remme W, Fox K, Ferrari R, Danser AH, Simoons ML; EUROPA-PERGENE investigators.

Cardiovasc Drugs Ther. 2009 Apr;23(2):171-81. doi: 10.1007/s10557-008-6156-1. Epub 2008 Dec 10.

PMID:
19082699
13.

Cardiologists' awareness and perceptions of guidelines for chronic heart failure. The ADDress your Heart survey.

Erhardt L, Komajda M, Hobbs FD, Soler-Soler J.

Eur J Heart Fail. 2008 Oct;10(10):1020-5. doi: 10.1016/j.ejheart.2008.08.001. Epub 2008 Sep 14.

14.

A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile.

Benner JS, Erhardt L, Flammer M, Moller RA, Rajicic N, Changela K, Yunis C, Cherry SB, Gaciong Z, Johnson ES, Sturkenboom MC, García-Puig J, Girerd X; REACH OUT Investigators.

Int J Clin Pract. 2008 Oct;62(10):1484-98. doi: 10.1111/j.1742-1241.2008.01872.x. Epub 2008 Aug 7.

15.

Gender aspects on survival among patients admitted to hospital with suspected or diagnosed heart failure.

Tasevska-Dinevska G, Kennedy LM, Cline-Iwarson A, Cline C, Erhardt L, Willenheimer R.

Scand Cardiovasc J. 2008 Dec;42(6):383-91. doi: 10.1080/14017430802226457.

PMID:
18615351
16.

Increased mortality after dronedarone therapy for severe heart failure.

Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crijns H, Amlie J, Carlsen J; Dronedarone Study Group.

N Engl J Med. 2008 Jun 19;358(25):2678-87. doi: 10.1056/NEJMoa0800456. Erratum in: N Engl J Med. 2010 Sep 30;363(14):1384.

17.

The From The Heart study: a global survey of patient understanding of cholesterol management and cardiovascular risk, and physician-patient communication.

Hobbs FD, Erhardt LR, Rycroft C; Heart study investigators.

Curr Med Res Opin. 2008 May;24(5):1267-78. doi: 10.1185/030079908X280491 . Epub 2008 Mar 19.

PMID:
18355420
18.
19.

Comprehensive cardiovascular risk management--what does it mean in practice?

Erhardt L, Moller R, Puig JG.

Vasc Health Risk Manag. 2007;3(5):587-603. Review. Erratum in: Vasc Health Risk Manag. 2008;4(3):741.

20.

Managing cardiovascular risk: the need for change.

Volpe M, Erhardt LR, Williams B.

J Hum Hypertens. 2008 Feb;22(2):154-7. Epub 2007 Sep 13. No abstract available.

PMID:
17855801

Supplemental Content

Loading ...
Support Center